Core Insights - Entrada Therapeutics, Inc. will participate in two upcoming investor conferences, highlighting its engagement with the investment community [1][2][3] Group 1: Upcoming Events - The CEO, Dipal Doshi, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 5:00 p.m. GMT [2] - Dipal Doshi will also participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 12:55 p.m. ET in Miami, FL [3] - Live webcasts of these events will be available on the Investor Relations section of the company's website, with replays accessible for 90 days post-event [3] Group 2: Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines targeting intracellular mechanisms previously deemed inaccessible [4] - The company's proprietary Endosomal Escape Vehicle (EEV™) therapeutics aim to enhance the intracellular delivery of various therapeutics, improving the therapeutic index [4] - Entrada is advancing a development portfolio that includes RNA- and protein-based programs for treating neuromuscular and ocular diseases, with lead programs targeting Duchenne muscular dystrophy [4]

Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [3] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics, aiming to improve therapeutic indices across various organs and tissues [3] - Entrada is advancing a diverse portfolio of RNA- and protein-based programs, particularly targeting neuromuscular and ocular diseases, with lead programs aimed at treating Duchenne muscular dystrophy [3] Recent Developments - On June 1, 2025, Entrada Therapeutics granted a total of 23,820 restricted stock units (RSUs) to six newly-hired non-executive employees as part of its 2025 Inducement Equity Plan [1] - The RSUs will vest incrementally, with one-fourth vesting on the one-year anniversary of the vesting commencement date, followed by quarterly vesting of 6.25% thereafter [2] - The inducement grants were approved by the Compensation Committee of the Board of Directors to incentivize new employees in accordance with Nasdaq Listing Rule 5635(c)(4) [1][2]